PCI Biotech Holding ASA (PCIB) - Total Assets
Based on the latest financial reports, PCI Biotech Holding ASA (PCIB) holds total assets worth Nkr18.52 Million NOK (≈ $1.95 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See PCI Biotech Holding ASA shareholders equity for net asset value and shareholders' equity analysis.
PCI Biotech Holding ASA - Total Assets Trend (2007–2024)
This chart illustrates how PCI Biotech Holding ASA's total assets have evolved over time, based on quarterly financial data.
PCI Biotech Holding ASA - Asset Composition Analysis
Current Asset Composition (December 2024)
PCI Biotech Holding ASA's total assets of Nkr18.52 Million consist of 99.0% current assets and 1.0% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr27.07 Million | 86.7% |
| Accounts Receivable | Nkr3.78 Million | 12.1% |
| Inventory | Nkr0.00 | 0.0% |
| Property, Plant & Equipment | Nkr310.00K | 1.0% |
| Intangible Assets | Nkr0.00 | 0.0% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how PCI Biotech Holding ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PCI Biotech Holding ASA market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PCI Biotech Holding ASA's current assets represent 99.0% of total assets in 2024, an increase from 0.0% in 2007.
- Cash Position: Cash and equivalents constituted 86.7% of total assets in 2024, down from 100.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2007.
- Asset Diversification: The largest asset category is cash and equivalents at 86.7% of total assets.
PCI Biotech Holding ASA Competitors by Total Assets
Key competitors of PCI Biotech Holding ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
PCI Biotech Holding ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.94 | 6.86 | 9.65 |
| Quick Ratio | 2.94 | 6.86 | 9.65 |
| Cash Ratio | 2.27 | 5.67 | 0.00 |
| Working Capital | Nkr11.66 Million | Nkr31.56 Million | Nkr204.65 Million |
PCI Biotech Holding ASA - Advanced Valuation Insights
This section examines the relationship between PCI Biotech Holding ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.48 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -29.1% |
| Total Assets | Nkr31.21 Million |
| Market Capitalization | $274.95K USD |
Valuation Analysis
Below Book Valuation: The market values PCI Biotech Holding ASA's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: PCI Biotech Holding ASA's assets decreased by 29.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for PCI Biotech Holding ASA (2007–2024)
The table below shows the annual total assets of PCI Biotech Holding ASA from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr31.21 Million ≈ $3.28 Million |
-29.14% |
| 2023-12-31 | Nkr44.05 Million ≈ $4.64 Million |
-30.61% |
| 2022-12-31 | Nkr63.48 Million ≈ $6.68 Million |
-53.31% |
| 2021-12-31 | Nkr135.98 Million ≈ $14.31 Million |
-34.98% |
| 2020-12-31 | Nkr209.12 Million ≈ $22.01 Million |
-25.85% |
| 2019-12-31 | Nkr282.03 Million ≈ $29.68 Million |
-21.01% |
| 2018-12-31 | Nkr357.06 Million ≈ $37.57 Million |
+511.02% |
| 2017-12-31 | Nkr58.44 Million ≈ $6.15 Million |
+160.90% |
| 2016-12-31 | Nkr22.40 Million ≈ $2.36 Million |
-60.29% |
| 2015-12-31 | Nkr56.40 Million ≈ $5.93 Million |
+176.71% |
| 2014-12-31 | Nkr20.38 Million ≈ $2.14 Million |
-61.35% |
| 2013-12-31 | Nkr52.74 Million ≈ $5.55 Million |
-32.56% |
| 2012-12-31 | Nkr78.20 Million ≈ $8.23 Million |
-21.93% |
| 2011-12-31 | Nkr100.17 Million ≈ $10.54 Million |
-12.55% |
| 2010-12-31 | Nkr114.54 Million ≈ $12.05 Million |
+175.82% |
| 2009-12-31 | Nkr41.53 Million ≈ $4.37 Million |
-23.91% |
| 2008-12-31 | Nkr54.58 Million ≈ $5.74 Million |
+5352.15% |
| 2007-12-31 | Nkr1.00 Million ≈ $105.33K |
-- |
About PCI Biotech Holding ASA
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vecto… Read more